default author photo

Sattva S. Neelapu

University of Texas at Houston - Department of Lymphoma and Myeloma

Houston, TX

United States

SCHOLARLY PAPERS

4

DOWNLOADS

168

TOTAL CITATIONS

0

Scholarly Papers (4)

1.

Safety and Activity of Lenalidomide in Combination with Obinutuzumab in Patients with Relapsed Indolent Non-Hodgkin Lymphoma: A Single Group, Open-Label, Phase 1/2 Trial

Number of pages: 42 Posted: 08 Apr 2024
University of Texas at Houston, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Biostatistics, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Translational Molecular Pathology, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma and University of Texas at Houston - Department of Lymphoma and Myeloma
Downloads 75 (837,727)

Abstract:

Loading...

Follicular Lymphoma, B-Cell Lymphoma, Lenalidomide, Therapeutic Use, Obinutuzumab, Antineoplastic Agents, Immunological

2.

Single Cell Clonotypic and Transcriptional Evolution of Multiple Myeloma Precursor Disease

Number of pages: 68 Posted: 09 Nov 2022
University of Texas at Houston - Department of Genomic Medicine, University of Texas at Houston - Department of Genomic Medicine, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Genomic Medicine, University of Texas at Houston - Department of Genomic Medicine, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Hematopathology, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Genomic Medicine, University of Texas at Houston - Department of Genomic Medicine, University of Texas at Houston - Department of Genomic Medicine, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Southern California - Keck School of Medicine, University of Southern California - Keck School of Medicine, University of Southern California - Keck School of Medicine, University of Southern California, University of Southern California, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Genomic Medicine and University of Texas at Houston - Department of Lymphoma and Myeloma
Downloads 60 (961,006)

Abstract:

Loading...

single-cell RNA sequencing (scRNAseq), multiple myeloma (MM), monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), single-cell B cell receptor sequencing (scBCR-seq), plasma cells (PCs), intra-tumoral heterogeneity (ITH), tumor microenvironment (TME), hyperdiploid (HY), non-hyperdiploid (non-HY)

3.

Targetable Cellular Etiology of Prolonged Cytopenia Following CD19 CAR T-Cell Therapy

Number of pages: 37 Posted: 09 Nov 2022
University of Texas at Houston - Department of Translational Molecular Pathology, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Translational Molecular Pathology, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma/Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Genomic Medicine, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Stem Cell Transplantation and Cellular Therapy, UT MD Anderson Cancer Center, University of Texas at Houston - Department of Lymphoma and Myeloma and University of Texas at Houston - Department of Lymphoma and Myeloma
Downloads 33 (1,277,121)

Abstract:

Loading...

CAR T-cell, B-cell lymphoma, Cytopenia, Interferon

4.

Safety and Activity of Pembrolizumab in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma

Posted: 01 Mar 2021
University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Biostatistics, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Biostatistics, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma and University of Texas at Houston - Department of Lymphoma and Myeloma

Abstract:

Loading...